Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Toxicological information

Developmental toxicity / teratogenicity

Currently viewing:

Administrative data

Endpoint:
developmental toxicity
Type of information:
experimental study
Adequacy of study:
weight of evidence
Reliability:
2 (reliable with restrictions)
Rationale for reliability incl. deficiencies:
data from handbook or collection of data
Justification for type of information:
Data from peer reviewed journal

Data source

Reference
Reference Type:
publication
Title:
Final report on the safety assessment of PEG-30, -33, -35, -36, and - 40 castor oil and PEG- 30 And -40 hydrogenated castor oil
Author:
Susan N. J. Pang
Year:
1997
Bibliographic source:
Cosmetic Ingredient Review; International Journal of Toxicology, 16:269-306,1997.

Materials and methods

Test guideline
Qualifier:
equivalent or similar to guideline
Guideline:
other: As mentioned below
Principles of method if other than guideline:
test material was tested for teratogenic effects in a feeding study with Sprague –Dawley rats for days 0 to 20 of gestation study period.
GLP compliance:
not specified
Limit test:
no

Test material

Constituent 1
Reference substance name:
Castor oil, hydrogenated, ethoxylated
IUPAC Name:
Castor oil, hydrogenated, ethoxylated
Constituent 2
Reference substance name:
Castor oil, hydrogenated, ethoxylated
EC Number:
500-147-5
EC Name:
Castor oil, hydrogenated, ethoxylated
IUPAC Name:
500-147-5
Constituent 3
Reference substance name:
61788-85-0
Cas Number:
61788-85-0
IUPAC Name:
61788-85-0
Details on test material:
- Name of test material (as cited in study report): PEG-40 Hydrogenated Castor Oil
- Substance type:Organic

Test animals

Species:
rat
Strain:
Sprague-Dawley
Details on test animals or test system and environmental conditions:
No details available

Administration / exposure

Route of administration:
oral: feed
Type of inhalation exposure (if applicable):
not specified
Vehicle:
other: diet
Details on exposure:
1) Two groups of pregnant rats, 30 in one group and 27 in the other were fed diets containing test substance.
2) Two control groups of 26 and 29 rats were fed untreated feed.
Analytical verification of doses or concentrations:
not specified
Details on mating procedure:
No details available
Duration of treatment / exposure:
0 to 20 days of gestation
Frequency of treatment:
Daily
Duration of test:
20 days
Doses / concentrations
Remarks:
Doses / Concentrations:
0,5000,10000 mg/kg
Basis:

No. of animals per sex per dose:
1st group: 30 pregnant rats.
2nd group: 27 pregnant rats.
1st control group: 26 pregnant rats.
2nd control group : 29 pregnant rats.
Control animals:
yes, concurrent vehicle
Details on study design:
No details available

Examinations

Maternal examinations:
All pregnant rats were observed for sign of toxicity during gestation and killed on day 20 for evaluation of the uteri.
Ovaries and uterine content:
Yes examined
Fetal examinations:
Yes examined for toxicity
Statistics:
No details available
Indices:
No details available
Historical control data:
No details available

Results and discussion

Results: maternal animals

General toxicity (maternal animals)

Clinical signs:
not specified
Dermal irritation (if dermal study):
not specified
Mortality:
not specified
Body weight and weight changes:
not specified
Food consumption and compound intake (if feeding study):
not specified
Food efficiency:
not specified
Water consumption and compound intake (if drinking water study):
not specified
Ophthalmological findings:
not specified
Haematological findings:
not specified
Clinical biochemistry findings:
not specified
Urinalysis findings:
not specified
Behaviour (functional findings):
not specified
Immunological findings:
not specified
Organ weight findings including organ / body weight ratios:
not specified
Gross pathological findings:
not specified
Neuropathological findings:
not specified
Histopathological findings: non-neoplastic:
not specified
Histopathological findings: neoplastic:
not specified
Other effects:
not specified

Maternal developmental toxicity

Number of abortions:
not specified
Pre- and post-implantation loss:
not specified
Total litter losses by resorption:
effects observed, treatment-related
Description (incidence and severity):
Slight but not statistically significant increase occurred in the number of resorptions in the group treated with 100000 mg/kg
Early or late resorptions:
not specified
Dead fetuses:
not specified
Changes in pregnancy duration:
not specified
Description (incidence and severity):
Migrated Data from removed field(s)
Field "Effects on pregnancy duration" (Path: ENDPOINT_STUDY_RECORD.DevelopmentalToxicityTeratogenicity.ResultsAndDiscussion.ResultsMaternalAnimals.MaternalDevelopmentalToxicity.EffectsOnPregnancyDuration): not specified
Changes in number of pregnant:
not specified
Other effects:
not specified
Details on maternal toxic effects:
Maternal toxic effects:no effects

Details on maternal toxic effects:
-No evidence of maternal toxicity was observed.
-Slight but not statistically significant increase occurred in the number of resorptions in the group treated with 10000 mg/kg

Effect levels (maternal animals)

Dose descriptor:
NOAEL
Effect level:
5 000 mg/kg bw/day (nominal)
Based on:
test mat.
Basis for effect level:
other: -Slight but not statistically significant increase occurred in the number of resorptions in the group treated with 100000 mg/kg
Remarks on result:
other: No toxic effects observed at 5000mg/kg dose group

Maternal abnormalities

Abnormalities:
not specified
Localisation:
not specified

Results (fetuses)

Fetal body weight changes:
not specified
Description (incidence and severity):
Migrated Data from removed field(s)
Field "Fetal/pup body weight changes" (Path: ENDPOINT_STUDY_RECORD.DevelopmentalToxicityTeratogenicity.ResultsAndDiscussion.ResultsFetuses.FetalPupBodyWeightChanges): not specified
Reduction in number of live offspring:
not specified
Changes in sex ratio:
not specified
Changes in litter size and weights:
not specified
Changes in postnatal survival:
not specified
External malformations:
not specified
Skeletal malformations:
not specified
Visceral malformations:
not specified
Other effects:
not specified
Details on embryotoxic / teratogenic effects:
Embryotoxic / teratogenic effects:no effects

Details on embryotoxic / teratogenic effects:
-The malformation and anomalies found in the fetuses of the experimental groups were similar to those found among the fetuses from the control groups which are not significant.
-No evidence of fetal toxicity was observed.

Effect levels (fetuses)

Dose descriptor:
NOAEL
Effect level:
10 000 mg/kg diet
Based on:
test mat.
Basis for effect level:
other: fetotoxicity
Remarks on result:
other: No developmental toxic effects pobserved

Fetal abnormalities

Abnormalities:
not specified
Localisation:
other: not specified

Overall developmental toxicity

Developmental effects observed:
not specified
Treatment related:
not specified
Relation to maternal toxicity:
not specified
Dose response relationship:
not specified
Relevant for humans:
not specified

Applicant's summary and conclusion

Conclusions:
The no observed adversed effect level (NOAEL) for teratogenicity study is considered to be 10000 mg/kg. When female rats were treated with test material orally.
Executive summary:

A teratogenic study was conducted to evaluate the fetal toxicity effects in the rat fetous by test compound to rats orally. In first group 30 pregnant rats and in second group 27 pregnant rats were fed diets containing test substance and in two control groups of 26 and 29 rats were fed untreated feed on daily basis for 20 days gestation period. During study period test animals were given 0(vehicle), 5000, 10000 mg/kg . Slight but not statistically significant increase occurred in the number of  resorptions in the group treated with 10000 mg/kg.Test material does not show the malformation and anomalies found in the fetuses of the experimental groups were similar to those found among the fetuses from the control groups which are not significant. Overall conclusion of the study is there was no evidence of the test substance shows any fetal toxicity. Hence the no observed adversed effect level (NOAEL) for teratogenicity study is considered to be 10000 mg/kg. When female rats were treated with test material orally.